

HOWREY LLP

321 NORTH CLARK STREET
SUITE 3400
CHICAGO, IL 60610
PHONE: 312.595.1239 • FAX: 312.595.2250

RECEIVED
CENTRAL FAX CENTER

JUL 21 2008

FACSIMILE COVER SHEET

DATE: July 21, 2008

TO: **NAME:** Examiner Karen A. Canella

COMPANY: U.S. Patent & Trademark Office - Group 1643

FAX NUMBER: 571-273-8300 **PHONE NUMBER:** 571-272-0828

CITY: Alexandria, VA

FROM: **NAME:** Kate Berezutskaya, Ph.D. **Direct Fax:** (312) 264-0364

DIRECT DIAL NUMBER: (312) 846-5622 **USER ID:** 2724

NUMBER OF PAGES, INCLUDING COVER: 3 **CHARGE NUMBER:** 03153.0005.NPUS00

☐ ORIGINAL WILL FOLLOW VIA:

☐ REGULAR MAIL

☐ OVERNIGHT DELIVERY

☐ HAND DELIVERY

☐ OTHER: _____

☒ ORIGINAL WILL NOT FOLLOW

SUPPLEMENTAL MESSAGE:

Re: Yu et al. - U.S. Application No. 09/938,623
"Lytic Peptide Prodrugs"
Filed: August 27, 2001
Our Reference No. 03153.0005.NPUS00

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS PRIVILEGED AND CONFIDENTIAL. IT IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ABOVE. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF THERE ARE ANY QUESTIONS OR PROBLEMS WITH THE TRANSMISSION OF THIS FACSIMILE, PLEASE CALL 312.595.1239

Docket No.: 03153.0005.NPUS00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER****JUL 21 2008**

Applicant(s): Xianzhong Yu et al.
App. No.: 09/938,623
Conf. No.:
Filing Date: August 27, 2001

Title: Lytic Peptide Prodrugs
Art Unit: 1643
Examiner: Karen A. Canella

RESPONSE TO EXAMINER'S AMENDMENTS**Attention: Examiner Karen A. Canella**

Dear Ms. Canella:

Applicants' representative has received the FAX of 07/19/08 with examiner's amendments for the above-identified patent application. The amendments are acceptable to Applicants. One of the proposed amendments is for claim 55 which when the amendment is entered will read as follows:

Claim 55. The method of claim 54 wherein said targeting molecule is selected from the group consisting of a molecule that targets neovasculature and an antibody.

Applicants note that Claim 55 depends from claim 54 which does not recite a targeting molecule. Thus, Applicants respectfully ask the Examiner to consider the following additional amendment to claim 55:

Claim 55. The method of claim 54 wherein said pore-forming cytolytic peptide further comprises a targeting molecule, wherein said targeting molecule is selected from the group consisting of a molecule that targets neovasculature and an antibody.

Application No.: 09/938,623

Docket No.: 03153.0005.NPUS00

RECEIVED
CENTRAL FAX CENTER

JUL 21 2008


Applicants respectfully believe that the instant application as amended is in good and proper order for allowance and early notification to this effect is respectfully solicited. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the instant application, the Examiner is encouraged to call the undersigned at (312) 846 5622.

Respectfully submitted,

HOWREY LLP

Dated: July 21, 2008

By:



Kate G. Berezutskaya, Ph.D.

Registration No.: 53,984

Customer No.: 22930

HOWREY LLP

ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-9922
Telephone No.: (703) 663-3600
Facsimile No.: (703) 336-6950